期刊文献+

多药联用综合治疗高血压合并糖尿病的临床疗效研究 被引量:4

Clinical Efficacy and Prognosis Analysis of Drug Combination Therapy for Hypertension Com- plicated with Diabetes
下载PDF
导出
摘要 [目的]探讨多药联合综合治疗高血压合并糖尿病的临床疗效。[方法]选取2015年6月至2016年6月本院收治的高血压合并糖尿病的患者94例,应用随机数字表法分为观察组与对照组,对照组患者给予常规降压药物治疗,治疗组患者采用多药联用综合治疗,对比两组患者的临床疗效,并对比治疗前后两组患者的收缩压(SBP)、舒张压(DBP)、空腹血糖(FPG)、血尿素氮(BUN)、血清肌酐(SCr)、血清钾(K+)及尿酸(UA)等变化。[结果]与对照组对比,观察组患者的总有效率为93.62%显著高于对照组的85.11%,差异有统计学意义(χ2=8.732,P〈0.05);与治疗前对比,治疗后两组患者的SBP、DBP及FPG水平均明显改善,且观察组患者的SBP、DBP及FPG水平较对照组患者改善更明显(P〈0.05);与治疗前对比,治疗后观察组患者的BUN及SCr均显著改善(P〈0.05),但UA及K+水平无显著改善,且两组比较无显著差异(P〉0.05)。[结论]多药联合综合治疗高血压合并糖尿病疗效显著,可有效控制患者病情,值得临床推广。 [ObjectivelTo explore the clinical efficacy of comprehensive treatment of hypertension compli- cated with diabetes by drug combination.[Methods]Ninety-four cases with hypertension complicated with dia- betic in our hospital from June 2015 to 2016 June were selected and divided into treatment group and control group according to the random number table method. Patients in the control group received conventional anti- hypertensive drug treatment, while those in the treatment group were treated with the drug in combination with comprehensive treatment. The clinical efficacy of the two groups was compared. Changes of systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FPG), blood urea nitrogen (BUN), serum creatinine (SCr), serum potassium (K+) and uric acid (UA) of the two groups of patients before and after treatment were compared with.[Results]Compared with the control group, the total effective rate of the treatment group was 93.62 %, significantly higher than that of the control group (85.11% ), the difference was statistically significant (χ2= 8.732, P 〈0.05); Compared with those before treatment, the levels of FPG, DBP and SBP were significantly improved in the two groups after treatment, and SBP, DBP and FPG levels in the treatment group were significantly better than those in the control group ( P 〈 0.05) Compared with those before treatment, BUN and SCr in the treatment group were significantly improved after treatment ( P 〈0.05) ; But there was no significant improvement in UA and K+ levels, and there was no significant differ- ence between the two groups ( P〉0.05).[ConclusionlComprehensive treatment of hypertension complicated With diabetes by drug combination has obvious curative effect, and can effectively control the patient's condi- tion. It is worthy of clinical promotion.
出处 《医学临床研究》 CAS 2016年第8期1536-1538,共3页 Journal of Clinical Research
关键词 高血压/并发症 糖尿病/药物疗法 药物疗法 联合 预后 Hypertension/CO Diabetes Mellitus/DTl Drug Therapy, Combinatiom Prognosis
  • 相关文献

参考文献8

二级参考文献103

  • 1王立军,马虹,廖新学,胡雪松,田方,顾海波,郝艳华,蔡乙明,彭龙云,何建桂,曾武涛,冷秀玉.替米沙坦对人血管内皮细胞血管紧张素转换酶-2表达的调节作用研究[J].中国危重病急救医学,2006,18(4):224-228. 被引量:16
  • 2李燕,张玉萍,韩新平.厄贝沙坦治疗高血压病合并2型糖尿病患者尿蛋白的临床分析[J].贵州医药,2006,30(10):925-926. 被引量:9
  • 3徐焱成.糖尿病患者合并高血压对降压药物的选择和应用[J].中国糖尿病杂志,2006,14(6):405-407. 被引量:57
  • 4曾惠莲,欧阳晓玲.苯那普利联合缬沙坦治疗早期糖尿病肾病临床观察[J].医学临床研究,2007,24(4):633-634. 被引量:2
  • 5Adler, A.I., Stratton, I.M., Neil, H.A., Yudkin, J.S., Matthews, D.R., Cull, C.A., Wright, A.D., Turner, R.C., Holman, R.R., 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 321(7258):412-419. [doi:10.1136/bmj.321.7258.412].
  • 6ADVANCE Collaborative Group, 2007. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 370(9590):829-840. [doi: 10.1016/S0140-6736(07)61303-8].
  • 7American Diabetes Association, 2011. Standards of medical care in diabetes--2011. Diabetes Care, 34(Suppl. 1): S11-$61. [doi:10.2337/dc11-S011].
  • 8Anderson, R.J., Bahn, G.D., Moritz, T.E., Kaufman, D., Abraira, C., Duckworth, W., for the VADT Study Group, 2011. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care, 34(1) 34-38. [doi:10.2337/dc10-1420].
  • 9Bangalore, S., Messerli, F.H., Wun, C.C., Zuckerman, A.L., DeMicco, D., Kostis, J.B., LaRosa, J.C., for the Treating to New Targets Steering Committee and Investigators, 2009. J-curve revisited: an analysis of the Treating to New Targets (TNT) trial. J. Am. Coll. Cardiol., 53:A217.
  • 10Bangalore, S., Messerli, F.H., Wun, C.C., Zuckerman, A.L., DeMicco, D., Kostis, J.B., LaRosa, J.C., for the Treating to New Targets Steering Committee and Investigators, 2010. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Eur. Heart J., 31(23):2897-2908. [doi:10. 1093/eurheartj/ehq328].

共引文献334

同被引文献11

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部